MEDH has been channel-trading in a wide range. Now, the stock is back at support as the whole cannabis space has corrected. A rinse-and-repeat channel technical opportunity in the making for active participants.
The company continues to expand and ramp up as a new entrant into the space.
MedX Holdings Inc (OTCMKTS:MEDH) is a new entrant into the US cannabis space that hasn’t yet been discovered by the crowd but appears to be a legitimate player, so it may be worth serious due diligence for speculators interested in earlier-stage opportunities.
The company just put out a new corporate update last week that could be instructive as to the company’s potential as a disruptive new player in the space. Broadly speaking, the update focuses on the company’s outlook for coming quarters, noting that, while its limited operations in 2020 were focused on management changes, 2021 will be about executing on business plans, including acquiring additional subsidiaries and effecting a name and symbol change.
MedX Holdings Inc (OTCMKTS:MEDH) CEO, Hans Enriquez, has reportedly embarked on several meaningful endeavors on behalf of the company. In December, for example, Hans participated as a speaker in the CBD Expo South, discussing merchant solutions in the CBD industry.
In late January, Mr. Enriquez also participated in a webinar hosted by international law firm, Harris Bricken, where Mexico’s entrance into the legal cannabis industry was discussed. In short, the company believes Mexico can present an array of opportunities as they seek international investment. The Company is purportedly exploring these opportunities in depth.
The company is also now performing extensive research into the emerging psychedelic medicine market. The use of psylocibin as a treatment for depression and PTSD is gaining notoriety and the Company believes it could be a significant growth industry. Stated CEO, Hans Enriquez: “I’m pleased with our progress during 2020 and in the first quarter of 2021. As my first-year anniversary approaches as MedX CEO, I’m pleased with what has been accomplished so far and I believe we’re on track to make this a big year for the Company, its subsidiaries and our shareholders.”
MedX Holdings Inc (OTCMKTS:MEDH) could, in other words, be a crossover play that represents exposure to the cannabis and psylocibin markets together, both being potentially extreme high-growth opportunities. Enriquez recently sat down with SmallCapVoice.com and details the company achievements in the first quarter of 2021 and the goals for the remainder of 2021. The interview focuses on the work being done by the Company on its hemp farm, the outlook for hemp in Texas and the entire US, other news and moves by MedX.
The company continues to expand and ramp up as a new entrant into the space.
MedX Holdings Inc (OTCMKTS:MEDH) is a new entrant into the US cannabis space that hasn’t yet been discovered by the crowd but appears to be a legitimate player, so it may be worth serious due diligence for speculators interested in earlier-stage opportunities.
The company just put out a new corporate update last week that could be instructive as to the company’s potential as a disruptive new player in the space. Broadly speaking, the update focuses on the company’s outlook for coming quarters, noting that, while its limited operations in 2020 were focused on management changes, 2021 will be about executing on business plans, including acquiring additional subsidiaries and effecting a name and symbol change.
MedX Holdings Inc (OTCMKTS:MEDH) CEO, Hans Enriquez, has reportedly embarked on several meaningful endeavors on behalf of the company. In December, for example, Hans participated as a speaker in the CBD Expo South, discussing merchant solutions in the CBD industry.
In late January, Mr. Enriquez also participated in a webinar hosted by international law firm, Harris Bricken, where Mexico’s entrance into the legal cannabis industry was discussed. In short, the company believes Mexico can present an array of opportunities as they seek international investment. The Company is purportedly exploring these opportunities in depth.
The company is also now performing extensive research into the emerging psychedelic medicine market. The use of psylocibin as a treatment for depression and PTSD is gaining notoriety and the Company believes it could be a significant growth industry. Stated CEO, Hans Enriquez: “I’m pleased with our progress during 2020 and in the first quarter of 2021. As my first-year anniversary approaches as MedX CEO, I’m pleased with what has been accomplished so far and I believe we’re on track to make this a big year for the Company, its subsidiaries and our shareholders.”
MedX Holdings Inc (OTCMKTS:MEDH) could, in other words, be a crossover play that represents exposure to the cannabis and psylocibin markets together, both being potentially extreme high-growth opportunities. Enriquez recently sat down with SmallCapVoice.com and details the company achievements in the first quarter of 2021 and the goals for the remainder of 2021. The interview focuses on the work being done by the Company on its hemp farm, the outlook for hemp in Texas and the entire US, other news and moves by MedX.